New cancer clinical trial: Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Published on: July 25, 2018 at 12:00PM
Conditions:   Triple -Negative Breast Cancer;   Estrogen Receptor Negative;   HER2/Neu Negative;   Anatomic Stage IV Breast Cancer AJCC;   Progesterone Receptor Negative
Interventions:   Procedure: Biopsy;   Procedure: Chemokine Modulation Therapy;   Drug: Celecoxib;   Biological: Recombinant Interferon Alfa-2b;   Drug: Rintatolimod;   Biological: Pembrolizumab
Sponsor:   Roswell Park Cancer Institute
Not yet recruiting
https://ift.tt/2K4z4do